AN UNBIASED VIEW OF PF-05221304

Procedure with SR18662 drastically minimizes advancement and proliferation of CRC cells. SR18662 shows enhanced efficacy in decreasing viability of multiple CRC cell traces. Flow cytometry Investigation adhering to SR18662 treatment demonstrates an increase in cells captured in possibly S or G2/M phases with the cell cycle and a big increase in the